Aspergillosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Our analysis suggests that the global aspergillosis therapeutics market was worth $1.6 billion in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 1.5% for the next eight years, to reach $1.9 billion by 2019. The aspergillosis therapeutics market is formed primarily by four classes of antifungal drugs: polyenes, triazoles, echinocandins and allylamines. The most prescribed drugs for the treatment of aspergillosis are Vfend, Noxafil, Cancidas, itraconazole and amphotericin B, of which the latter two...
View full press release